Denali Therapeutics Inc. (DNLI): Total Liabilities
$131.09M
As of 2025-12-31
$322.78M
As of 2026-06-30
-32.0%
3-year compound annual growth
-22.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $131.09M | -9.3% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $144.50M | +17.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $122.96M | -70.6% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $417.81M | -5.4% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $441.87M | -2.6% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $453.75M | +186.6% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $158.34M | +37.5% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $115.14M | +450.2% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $20.93M | n/a | 2019-03-12, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | $131.09M | -9.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $22.92M | -19.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $11.18B | -1.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.38B | +22.1% |
Compare DNLI, VXRT, RGEN, CSBR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗